Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for Ibtrozi (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer
NDA FilingapprovedIbtroziPositive
AI Analysis
Summary
Nuvation Bio announced FDA approval of a supplemental new drug application for Ibtrozi (taletrectinib) in TKI-naïve advanced ROS1-positive non-small cell lung cancer with updated duration of response data. This approval represents a significant regulatory milestone for the company's oncology asset.
Outcome Details
FDA approved supplemental new drug application with updated duration of response data
Importance:8/10
Sentiment:
0.90
FDA approvalsupplemental NDAoncologyROS1-positive NSCLCtaletrectinib
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 16, 2026 9:09 PM